Reuters reports on GLP-1 users turning to repair shops as their bodies change. Tap through for the full story on where the drugs are reaching everyday businesses.
Recap by typeshit. Full story at Reuters.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
The endocrinologist says fear, judgment and misinformation still shape how people see GLP-1 drugs, and asks patients to learn before deciding.
The rise was driven by new generics and steady prices, with Eli Lilly's tirzepatide named in the market breakdown.
Loading…